INCY Q2 net income +45% to $585.6M on $246M OPZELURA settlement, JAKAFI XR launch

Filed July 28, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 29, 2025 · ~2 min read

Key Changes

• high

  OPZELURA CMS settlement reversed $246M in Medicaid rebate accruals (one-time non-cash benefit) and eliminates future accruals, improving gross-to-net economics going forward. CMS agreed not to treat OPZELURA as a JAKAFI line extension.

  MD&A: OPZELURA CMS litigation settlement verify on EDGAR →
• high

  JAKAFI XR (extended-release formulation) approved by FDA in May 2026 for same indications as original JAKAFI, offering once-daily dosing. Q2 2026 net sales include both products following launch.

  MD&A: JAKAFI XR approval and launch verify on EDGAR →
• high

  Phase 3 frontMIND trial met primary endpoint (progression-free survival) and key secondary endpoint (event-free survival) for tafasitamab + lenalidomide + R-CHOP as first-line DLBCL therapy, potentially expanding into larger first-line market.

  MD&A: frontMIND trial positive topline results verify on EDGAR →